Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1399 articles about Regeneron Pharmaceuticals, Inc.
-
5 Top Companies Hiring Oncology Jobs
4/18/2024
Looking for oncology jobs in the biopharma industry? Check out these five top companies hiring life sciences professionals like you. -
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
-
The U.S. Department of Justice has filed a complaint against Regeneron alleging that the pharma knowingly omitted credit card price concessions for Eylea to inflate Medicare reimbursement rates.
-
With the American Association for Cancer Research’s annual conference well underway, data from vaccines and other products targeting tough-to-treat cancers have dominated the program.
-
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
4/7/2024
Regeneron Pharmaceuticals, Inc. announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma at the American Association for Cancer Research Annual Meeting 2024 in San Diego.
-
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
-
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
4/1/2024
2seventy bio, Inc., announced the completion of the asset purchase agreement by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.
-
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
4/1/2024
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 2, 2024, before the U.S. financial markets open.
-
5 Top Companies Hiring in New Jersey
3/28/2024
Looking for a biopharma job in New Jersey? Check out the BioSpace list of five top companies hiring life sciences professionals like you. -
Regeneron Provides Update on Biologics License Application for Odronextamab
3/25/2024
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) and in R/R diffuse large B-cell lymphoma (DLBCL), each after two or more lines of systemic therapy.
-
Regeneron’s bispecific antibody odronextamab was hit with Complete Response Letters from the FDA noting issues with the enrollment status of its confirmatory trials.
-
An appellate court sided with Regeneron versus Novartis on Monday, agreeing that anti-VEGF pre-filled syringes constitute a distinct market than those sold in vials. The case involves Regeneron’s Eylea and Novartis’ Lucentis eye treatments.
-
The FDA will close out a hectic month of March with a flurry of target action dates, including ones for lymphoma and CKD anemia treatments.
-
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
3/11/2024
Regeneron Pharmaceuticals, Inc. announced the U.S. Food & Drug Administration has extended the approval of Praluent® as an adjunct to diet and other low-density lipoprotein cholesterol lowering therapies to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.
-
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
3/8/2024
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for EYLEA® HD (aflibercept) Injection 8 mg.
-
Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.
-
The FDA’s target decision date is June 27, 2024, the companies announced Friday. Sanofi and Regeneron are looking to expand blockbuster Dupixent into chronic obstructive pulmonary disease.
-
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
2/21/2024
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies.
-
Two surprise companies, Vertex Pharmaceuticals and Regeneron Pharmaceuticals, made GlobalData’s list with 41.4% and 21.8% market capitalization growth, respectively.
-
Regeneron Announces Investor Conference Presentations - February 06, 2024
2/6/2024
Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.